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ABSTRACT
INTRODUCTION Menière’s disease (MD) is an uncommon cause of sudden profound vertigo. A variety of medical and surgical
treatments have been used to manage this condition. This study reviewed the outcomes of patients treated with grommet
insertion and transtympanic steroid injection.
METHODS Patients diagnosed with MD between 2007 and 2017 were identified, and case notes and audiological data were
retrieved for those managed by grommet (ventilation tube) insertion with and without transtympanic steroid injection.
RESULTS Thirty-three patients were identified as being diagnosed with MD. Grommet insertion resulted in cessation or
improvement of attacks in 91% of cases. The mean follow-up duration was 33.8 months (median: 29 months). The mean
hearing threshold across the low frequencies improved from 57.2dBHL to 49.4dBHL (p=0.031). Following the intervention,
improved tinnitus was reported in 80% of cases. Twelve patients (36%) reported aural fullness prior to grommet insertion; all
reported improved symptoms following the procedure.
CONCLUSIONS Early grommet insertion with transtympanic steroid injection, combined with customised vestibular physiotherapy,
may provide an alternative first-line strategy for MD, preventing further true MD attacks. In some patients, it may significantly
improve hearing thresholds.
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Introduction
Menière’s disease (MD) is an uncommon cause of vertigo
with an estimated incidence of 4.3–8.2 cases per 100,000
per annum.1,2 This condition is characterised by spontane-
ous unpredictable bouts of aural fullness, severe vertigo,
hearing loss and roaring tinnitus.3 Sequential pure tone
audiometry demonstrating a sensorineural hearing loss
and magnetic resonance imaging (MRI) of the internal
auditory meatuses to exclude central pathology are essen-
tial to confirm a clinical diagnosis.
Histological studies have revealed expansion of the scala
media with intermittent acute attacks attributed to rupture
of Reissner’s membrane, and subsequent mixing of peril-
ymph and endolymph.4,5 This results in toxic overexcita-
tion of the organ of Corti and vestibular neuroepithelium,
with eventual severe sensorineural hearing loss and a
reduction in peripheral vestibular function.
As the disease progresses, sensorineural hearing loss
worsens in a characteristic stepwise fashion that is associ-
ated with profound spells of vertigo.6 Patients with end
stage disease are prone to spells of dizziness, decompensa-
tion (which may be misinterpreted as acute attacks) and
sudden drop attacks (Tumarkin attacks).7 Severe
sensorineural hearing loss and partial residual vestibular
function is often found in a ‘burnt out’ ear. Symptoms are
initially unilateral but may be bilateral.8
Grommet (ventilation tube) insertion is a relatively sim-
ple procedure that has been advocated by some surgeons
in the treatment of MD.9 Although the mechanism of action
has been attributed to pressure change in the middle ear,
tympanometry does not always support the presence of
negative middle ear pressure. The aim of this study was to
perform a retrospective review of the outcome of patients
diagnosed with MD who were treated with grommet inser-
tion only, and of those treated with grommet insertion and
transtympanic steroid injection.
Methods
Patients diagnosed with MD between 2007 and 2017 were
identified and their case notes reviewed. A diagnosis of
MD was made based on each patient fulfilling all four of
the following criteria:
> a history consistent with MD
> a fluctuating sensorineural hearing loss confirmed by
pure tone audiometry
> normal MRI of the internal auditory meatus
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> a peripheral vestibular deficit confirmed by bithermal
caloric testing or suggested by a significant directional
preponderance
All patients managed by grommet insertion were identi-
fied. All cases were referred to a specialist vestibular physi-
otherapist for customised vestibular rehabilitation after
surgery. Hearing outcomes were assessed by pure tone
audiometry before and approximately three months after
the procedure. Following the intervention, the frequency
and severity of vertiginous episodes was noted, as was the
effect of grommet insertion on tinnitus. These patient
reported outcome measures were assessed with a value of
-1 denoting worsening symptoms, 0 denoting unaltered
symptomatology and +1 denoting symptom improvement.
Statistical analysis
The paired t-test was used to compare hearing thresholds
following normality assessment with the Kolmogorov–
Smirnov test. The Wilcoxon signed-rank test was used for
comparison of non-parametric treatment effect outcomes.
A p-value of <0.05 was considered statistically significant.
SPSS® version 24.0 (IBM, New York, US) was employed for
data analysis.
Results
A total of 33 patients were identified as being diagnosed
with MD. The majority were female (n=24, 72.7%). The
mean patient age was 46.0 years (standard deviation: 12.4
years). The duration of symptoms exceeded two years in
three-quarters of the patients (n=24, 72.7%). The mean fol-
low-up duration was 33.8 months (median: 29 months,
range: 12–88 months).
The right ear was most commonly affected (n=20,
60.8%). A previous or concurrent diagnosis of vestibular
(vertiginous) migraine was made in seven cases (21.2%)
and treated accordingly. One patient had been previously
diagnosed with benign paroxysmal positional vertigo.
Three patients (9.1%) had undergone previous grommet
insertion for MD prior to referral. Five patients (15.5%)
underwent more than one grommet insertion procedure
on the same ear; two patients had a total of three inser-
tions and three patients a total of two insertions.
Patients receiving transtympanic steroids had grommet
insertion under general anaesthesia, with the ventilation
tube inserted into the anteroinferior quadrant of the tym-
panic membrane. Methylprednisolone (80mg in 2ml) was
injected into the middle ear through the tympanic
membrane prior to grommet insertion. The volume of ste-
roid injected was variable and it often spilt into the exter-
nal auditory canal.
A Shah grommet was the ventilation tube of choice in
the majority of cases (n=32, 97.0%) and the initial grommet
employed in every patient. A Triune tube was used in one
patient and a T-tube in a further two patients. Transtym-
panic steroid injection was performed in 26 patients
(78.8%). No adverse effects of grommet insertion or trans-
tympanic steroid injection were reported.
Vertigo
Symptoms of vertigo were resolved or improved following
grommet insertion in 30 patients (91.0%). Among these,
attacks of MD settled but vestibular migraine and spells of
decompensation symptoms persisted.
Two patients (6.1%) reported no change in their symp-
toms after the intervention. These individuals underwent
both grommet insertion and transtympanic steroid
injection.
Hearing level
For the entire study cohort, the mean hearing threshold
across the low frequencies improved from 57.2dBHL to
49.4dBHL. The treatment effect (expressed as the differ-
ence between the mean hearing thresholds before and
after treatment) was 7.8dBHL. This was a statistically sig-
nificant improvement (p=0.031). The high frequency hear-
ing thresholds and overall hearing were not significantly
altered by the intervention (Table 1).
Subgroup analysis of hearing thresholds for those
patients who had grommets and transtympanic steroids
showed a sustained significant improvement of the low fre-
quency thresholds with a mean difference of 19.0dBHL
(p=0.046) (Table 2). Seven patients had grommet insertion
alone, with no significant alteration of their hearing
thresholds (Table 3).
Five patients underwent grommet insertion on two or
more occasions. Pairwise comparisons revealed that the
mean difference across the high frequencies and the over-
all mean difference across all frequencies deteriorated sig-
nificantly between the second and third insertion (p<0.05)
with no significant hearing changes for the remaining
comparisons (p>0.05) (Table 4).
Tinnitus and aural fullness
Fifteen patients (45.5%) reported tinnitus prior to grommet
insertion. Of these, 12 (80.0%) felt that the tinnitus
Table 1 Change in mean hearing threshold for entire cohort
Before grommet (n=33) After grommet (+/- steroid) (n=33) Mean difference p-value
Hearing level 55.9dBHL (SD: 15.7dBHL) 52.5dBHL (SD: 20.4dBHL) 3.4dBHL 0.240
Low frequencies 57.2dBHL (SD: 16.1dBHL) 49.4dBHL (SD: 22.2dBHL) 7.8dBHL 0.031
High frequencies 54.7dBHL (SD: 18.8dBHL) 55.6dBHL (SD: 20.9dBHL) -0.9dBHL 0.757
SD = standard deviation
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improved following the intervention. Of the remaining
patients, one had worsening symptoms while two
described their symptoms as unchanged. All three received
grommets alone.
Twelve patients (36.4%) reported aural fullness prior to
treatment. All of these individuals had improved symptoms
following the grommet insertion.
When considering the entire study cohort, the treatment
effect was positive for all three symptoms, with the effects
being statistically significant (p<0.01). This was also the
case for the subgroup of patients receiving steroid injec-
tion, with significant improvements for all symptoms
(p<0.01). For patients who had grommet insertion alone,
however, there was no statistically significant improvement
in tinnitus (p=0.317) but vertigo attacks and aural fullness
did improve significantly (p=0.005 and p=0.025 respec-
tively). Symptoms were improved for the whole cohort
while the grommet remained in place, and they recurred
during and following grommet extrusion.
Discussion
A variety of medical and surgical treatments have been
suggested for the treatment of MD. Medical therapies
include betahistine,10 a histamine analogue that is believed
to increase bloodflow to the inner ear, while diuretics such
as bendroflumethiazide are thought to reduce the expan-
sion of the endolymph compartment. Cochrane reviews on
both medications have found no good evidence as to their
efficacy in reducing the frequency or severity of
attacks.11,12 Vestibular sedatives (eg prochlorperazine) and
antihistamines (eg cyclizine and cinnarizine) are recom-
mended for acute attacks based on their license of use and
expert opinion but evidence regarding their efficacy is
lacking.13
Transtympanic interventions include the use of steroid
injections such as methylprednisolone14 and gentamicin
ablation.15,16 Both interventions reduce the number of ver-
tigo attacks in patients with MD in the six months follow-
ing treatment. Gentamicin ablation has been a popular
method for controlling acute attacks of vertigo in MD
patients by destroying vestibular function in the affected
ear.16 However, ablative treatments should be used with
caution as this condition may affect both ears in over 40%
of cases over a 20-year period.7,14 Bilateral vestibular hypo-
function is extremely difficult to manage, with many
patients wheelchair bound and severely psychologically
affected.17 It could be argued that a ‘burnt out’ MD ear
with reduced vestibular function may be preferential to an
inner ear with absent function (as the latter may be more
difficult to rehabilitate using vestibular rehabilitation exer-
cises). Furthermore, with increasing life expectancy, more
MD patients are likely to survive to develop multilevel
vestibulopathy.
Surgical approaches include endolymphatic sac depres-
sion, surgical labyrinthectomy and vestibular nerve
Table 2 Change in mean hearing threshold for patients with grommet insertion and steroid injection
Before grommet (n=26) After grommet (+ steroid) (n=26) Mean difference p-value
Hearing level 56.4dBHL (SD: 16.6dBHL) 52.3dBHL (SD: 22.3dBHL) 4.1dBHL 0.249
Low frequencies 67.5dBHL (SD: 17.1dBHL) 48.5dBHL (SD: 24.3dBHL) 19.0dBHL 0.046
High frequencies 55.4dBHL (SD: 19.9dBHL) 56.1dBHL (SD: 22.4dBHL) -0.7dBHL 0.832
Table 3 Change in mean hearing threshold for patients with grommet insertion only
Before grommet (n=7) After grommet (no steroid) (n=7) Mean difference p-value
Hearing level 54.2dBHL (SD: 12.7dBHL) 53.3dBHL (SD: 11.9dBHL) 0.9dBHL 0.837
Low frequencies 55.9dBHL (SD: 12.9dBHL) 52.9dBHL (SD: 13.0dBHL) 3.0dBHL 0.340
High frequencies 52.4dBHL (SD: 14.6dBHL) 53.8dBHL (SD: 15.6dBHL) -1.4dBHL 0.788
Table 4 Repeated events analysis: estimated marginal means
Grommet insertion Low frequency mean difference High frequency mean difference Total threshold difference
1st 8.0dBHL -0.4dBHL 3.8dBHL
2nd 3.6dBHL 4.1dBHL 2.4dBHL
3rd 0.2dBHL -5.6dBHL -3.9dBHL
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section.18 Tenotomy of the tensor tympani and stapedius
tendons for MD has also been described to abolish or
reduce attacks.19–21 One mechanism, suggested by Loader,
is that endocochlear hydrops results in an elevated intraco-
chlear pressure that is displaced on to the ossicular
chain.22 This leads to increased rigidity and reduced mobi-
lity of the ossicles. Sudden spikes in inner ear pressure
and rupture of Reissner’s membrane account for the pro-
found and spontaneous bouts of vertigo, hearing loss and
tinnitus experienced by patients. Severing the tendons of
the stapedius and tensor tympani muscles eliminates the
medial force vector of the middle ear ossicles, and this
accounts for the improvement in symptoms demonstrated
when using this approach.
A curious observation (and one supported by this case
series) is that grommet insertion may prevent acute
attacks, and partially restore and maintain sensorineural
thresholds in the affected ear.3 Patients report aural full-
ness and recurrent attacks on grommet extrusion.
We suggest that grommet insertion may act by a similar
mechanism to that proposed previously. Insertion of a ven-
tilation tube could result in a change in tension of the
ossicular chain. This limits the forces exerted on the basi-
lar membrane to thresholds below those that result in
Reissner’s membrane rupture, even though this compart-
ment may be gradually expanding. In our series, grommet
insertion resulted in dramatic improvement in sensorineu-
ral hearing thresholds and cessation of acute attacks. The
sensorineural change is likely to be due to a change in the
tension of the middle and hence inner ear, to within a ten-
sile range that supports improved hearing of certain
frequencies.24,25
Study limitations
Although the data in this study indicate that grommet
insertion is a promising and relatively low risk surgical
treatment for MD, our analysis has several limitations.
This was a retrospective review, with inherent selection
bias. It included only a small number of patients and there
was no comparison with a control group. In addition, no
dizziness questionnaires were employed. We would there-
fore recommend a formal prospective case series or rando-
mised controlled trial assessing this approach in the
management of MD.
Conclusions
Our findings indicate that early transtympanic steroid
injection and grommet insertion, along with customised
vestibular physiotherapy, may provide an alternative first-
line strategy for the treatment of MD. The results pre-
sented imply that this approach prevents attacks and (in
some patients) significantly improves hearing thresholds.
We suggest a formal prospective case series or randomised
controlled trial is undertaken, comparing this method with
other treatment options currently available.
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